Pippa Gledhill

Cell Therapy 2.0

The first CAR T approvals were a major turning point for the cell therapy field. Now, companies are shifting their focus to the next wave: off-the-shelf (allogeneic) approaches, CAR T and TCR therapy for solid tumors, and combinations with immune checkpoint modulators.